Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
19 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an...
Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
12 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will be among the companies providing presentations at the Alliance for Regenerative...
Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
21 mars 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 21, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will participate in two upcoming investment banking conferences, Oppenheimer’s 28th Annual...
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
14 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
Planning to Initiate HOPE-2 Clinical Trial To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 14, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
08 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 08, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor to Host Key Opinion Leader Lunch on March 9
28 févr. 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it will host a Key Opinion Leader Lunch in New York City on March 9 featuring four distinguished...
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
22 févr. 2018 13h23 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart...
Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
12 févr. 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) will provide an update on HOPE-2, its trial for CAP-1002, the company’s lead investigational therapy for the...
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
05 févr. 2018 11h11 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational...
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
16 janv. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) announced today that it has added seven new patent applications to its existing Exclusive License Agreements with...